ARTICLE | Company News
D-Pharm, Jiangsu NHWA deal
June 6, 2011 7:00 AM UTC
D-Pharm granted NHWA exclusive rights to develop and commercialize DP-VPA in China for epilepsy. D-Pharm will be eligible to receive up to $2.4 million in upfront and milestones payments, plus 5% roy...